Interferon Beta-1A is a recombinant, glycosylated cytokine belonging to the Type I interferon family. It is a potent immunomodulator and antiviral agent, primarily used in the management of relapsing forms of Multiple Sclerosis (MS). It is produced in Chinese Hamster Ovary (CHO) cells and mimics the natural human interferon beta protein. In the Indian context, it is a critical disease-modifying therapy (DMT) for MS, helping to reduce the frequency and severity of clinical exacerbations and slow the accumulation of physical disability.
Adult: 250 micrograms (mcg) administered intramuscularly (IM) once weekly. Initiation under medical supervision is recommended.
Note: For IM use only. Reconstitute the lyophilized powder with the supplied diluent (sterile water for injection). Gently swirl to dissolve; do not shake vigorously. Administer immediately after reconstitution. The preferred site is the upper outer quadrant of the gluteal muscle. Rotate injection sites with each dose. Pre-medication with acetaminophen/NSAIDs can help manage flu-like symptoms.
Interferon Beta-1A exerts its therapeutic effects in MS through complex immunomodulatory mechanisms. It binds to the Type I interferon receptor (IFNAR) on the surface of various immune cells, leading to the activation of the JAK-STAT signaling pathway. This results in the downstream regulation of over 100 genes, modulating the immune response.
Pregnancy: Pregnancy Category C (US FDA). Animal studies have shown abortifacient effects. Human data are limited. Use only if the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should use effective contraception. A pregnancy registry is recommended.
Driving: May cause fatigue, dizziness, and asthenia. Patients should be cautioned about operating machinery or driving until they know how the medication affects them.
| Myelosuppressive agents (e.g., Cladribine, Cyclophosphamide, Azathioprine) | Additive risk of bone marrow suppression (leukopenia, thrombocytopenia). | Major |
| Hepatotoxic drugs (e.g., high-dose Paracetamol, Methotrexate, Isoniazid, certain anticonvulsants) | Increased risk of hepatotoxicity and elevated liver enzymes. | Major |
| Theophylline | Interferon Beta may reduce the clearance of Theophylline, increasing its plasma levels and risk of toxicity. | Moderate |
| Zidovudine (AZT) | Increased risk of hematologic toxicity (neutropenia, anemia). | Moderate |
| Live attenuated vaccines | Theoretical risk of enhanced vaccine replication and infection due to immunomodulation. Avoid concurrent use. | Major |
Same composition (Interferon Beta-1A (250mcg)), different brands: